Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor
Interventions: DRUG: CLR457
Sponsor: Novartis Pharmaceuticals